Oral IRAK-4 inhibitor CA-4948 is blood-brain barrier penetrant and has single-agent activity against CNS lymphoma and melanoma brain metastases.

Christina A von Roemeling Bently P Doonan Kelena Klippel Daniel C Schultz Lan Hoang-Minh Vrunda Trivedi Chenglong Li Rylynn Russell Siva Rama Raju Kanumuri Abhisheak Sharma Han W Tun Duane A Mitchell

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

IRAK-4 is an attractive target in PCNSL and MBM. The inhibition of IRAK-4 with CA-4948 downregulates the expression of important transcription factors involved in tumor growth and proliferation. CA-4948 is currently being investigated in clinical trials for relapsed and refractory lymphoma and warrants further translation into PCNSL and MBM.

Keyphrases

blood brain barrier
diffuse large b cell lymphoma
brain metastases
clinical trial
small cell lung cancer
transcription factor
cerebral ischemia
protein kinase
poor prognosis
acute myeloid leukemia
acute lymphoblastic leukemia
signaling pathway
binding protein
hodgkin lymphoma
study protocol
single molecule